Search tips
Search criteria 


Logo of plosonePLoS OneView this ArticleSubmit to PLoSGet E-mail AlertsContact UsPublic Library of Science (PLoS)
PLoS One. 2016; 11(6): e0158525.
Published online 2016 June 29. doi:  10.1371/journal.pone.0158525
PMCID: PMC4927154

Sequence Analysis of In Vivo-Expressed HIV-1 Spliced RNAs Reveals the Usage of New and Unusual Splice Sites by Viruses of Different Subtypes

Emanuele Buratti, Editor


HIV-1 RNAs are generated through a complex splicing mechanism, resulting in a great diversity of transcripts, which are classified in three major categories: unspliced, singly spliced (SS), and doubly spliced (DS). Knowledge on HIV-1 RNA splicing in vivo and by non-subtype B viruses is scarce. Here we analyze HIV-1 RNA splice site usage in CD4+CD25+ lymphocytes from HIV-1-infected individuals through pyrosequencing. HIV-1 DS and SS RNAs were amplified by RT-PCR in 19 and 12 samples, respectively. 13,108 sequences from HIV-1 spliced RNAs, derived from viruses of five subtypes (A, B, C, F, G), were identified. In four samples, three of non-B subtypes, five 3’ splice sites (3’ss) mapping to unreported positions in the HIV-1 genome were identified. Two, designated A4i and A4j, were used in 22% and 25% of rev RNAs in two viruses of subtypes B and A, respectively. Given their close proximity (one or two nucleotides) to A4c and A4d, respectively, they could be viewed as variants of these sites. Three 3’ss, designated A7g, A7h, and A7i, located 20, 32, and 18 nucleotides downstream of A7, respectively, were identified in a subtype C (A7g, A7h) and a subtype G (A7i) viruses, each in around 2% of nef RNAs. The new splice sites or variants of splice sites were associated with the usual sequence features of 3’ss. Usage of unusual 3’ss A4d, A4e, A5a, A7a, and A7b was also detected. A4f, previously identified in two subtype C viruses, was preferentially used by rev RNAs of a subtype C virus. These results highlight the great diversity of in vivo splice site usage by HIV-1 RNAs. The fact that four of five newly identified splice sites or variants of splice sites were detected in non-subtype B viruses allows anticipating an even greater diversity of HIV-1 splice site usage than currently known.


HIV-1 RNAs are transcribed from a single promoter at the 5’ long terminal repeat and their relative expression is regulated through the alternative usage of splice sites. According to splicing events involved in their generation, HIV-1 transcripts are assigned to three major categories [16] (Fig 1): (1) unspliced RNA, coding for Gag-Pol and Pol polyproteins; (2) doubly spliced (DS) transcripts, generated by excision of major introns overlapping Gag-Pol and Vpu and Env open reading frames, coding for Tat, Rev, Nef, and Vpr proteins; and (3) singly spliced (SS) transcripts, generated by excision of the Gag-Pol intron, coding for Env, Vpu, Vif, Vpr, and a truncated Tat protein. The doubly or singly spliced RNA designations, employed here and in the literature, do not reflect the total number of splicing events but instead represent the number of major splicing events, with the exception of a singly spliced 1.7 Nef-encoding RNA, which is usually assigned to the DS category (Fig 1). A fourth category of short spliced RNAs, using 3’ splice sites (3’ ss) near the HIV-1 genome’s 3’ end, has been identified in two isolates in vitro and in a minority of viruses in vivo [79]; however, their frequency of expression, relative abundance, and function still remain to be defined. The complexity of HIV-1 splicing is further increased by several additional factors: (1) the usage of redundant closely spaced 3’ss for generation of rev RNAs, of which eight have been reported [1,6,913]; (2) the optional incorporation of small noncoding exons in the leader sequence (in addition to the 5’-terminal exon 1, common to all HIV-1 spliced RNAs): exons 2 or 3 or both in tat, rev, nef, and env-vpu RNAs, and exon 2 in vpr RNAs [16]; (3) the uncommon usage of other splice sites in some isolates [1,79,1418].

Fig 1
Schematic depiction of HIV-1 splicing and locations of PCR primers.

The stability and nucleo-cytoplasmic transport of unspliced and SS transcripts requires the build-up of a certain threshold of Rev protein concentration. This determines that HIV-1 RNAs are expressed in a temporally-regulated fashion: DS transcripts, whose cytoplasmic expression is Rev-independent, are detected first, and, subsequently, after a certain concentration of Rev protein is reached, SS and unspliced RNAs are expressed [19,20].

Most HIV-1 RNA splice sites exhibit suboptimal efficiencies [2125], which allow for the regulation of their relative usage through the action of cellular splicing regulatory factors binding to splice enhancer or suppressor elements in the HIV-1 genome [26]. The alterations in balanced splicing of HIV-1 transcripts may exert a strong negative effect on viral replication. These may be provoked by mutations in splice sites [6,27] or splice regulatory elements [2830], or affecting RNA secondary structure at splice sites [31,32], or by manipulations in the expression of cellular splicing regulatory proteins [30,33].

The great majority of studies on HIV-1 RNA splicing have been performed with isolates of subtype B, which is predominant in Western countries. Published reports on non-subtype B viruses are limited to the study of two group O [11,34] and three subtype C [12] isolates. In these studies, RNA splice sites used by rev RNAs previously unreported in subtype B viruses were identified: A4e in a group O virus [11], A4f in two subtype C viruses, and A4g in one subtype C virus [12].

The majority of studies on HIV-1 splicing have been carried out in in vitro assays using a limited number of cell line-adapted isolates [16,9,16,35,36]. Most studies on in vivo expression of HIV-1 RNAs were limited to examining the expression of different transcript categories without analyzing individual transcripts within each category [3648]. To our knowledge, only two studies analyzing in vivo expression of individual HIV-1 transcripts have been published, and in only one of them sequencing was used. In the first study [49], HIV-1 splicing patterns were analyzed in peripheral blood mononuclear cells (PBMCs) of HIV-1-infected individuals by reverse transcriptase polymerase chain reaction (RT-PCR) using a radiolabeled primer. Amplified products were identified according to their size through denaturing polyacrylamide gel electrophoresis. It was observed that the splicing patterns in each patient were conserved over the years and differed between individuals. Usage of splice sites was generally consistent with previous in vitro findings. The second study involved sequencing clones of RT-PCR products derived from DS and SS HIV-1 RNAs, amplified from PBMCs from 5 HIV-1-infected individuals, but only 94 clones were sequenced (10–31 per individual) [8].

In this study, we analyze in vivo HIV-1 splice site usage within the DS and SS categories through pyrosequencing using a greater number of clinical samples from HIV-1-infected individuals than in previous in vivo studies [8,49]. Since RNA splicing patterns may vary according to cell type [2,35,50] and activation state [5155], a more homogeneous cell population was also used. For this, we isolated CD4+CD25+ lymphocytes, representing the activated T-lymphocyte population, obtained from 19 HIV-1-infected individuals at different stages of the infection. These cells were chosen because, among circulating cells, they represent the source of the great majority of HIV-1 virions [5658]. The results allowed the detection of the in vivo usage of five new HIV-1 RNA splice sites, four of them in non-subtype B viruses, and several unusual ones.

Materials and Methods

Ethics statement

Written informed consent was obtained from all participants in the study, which was approved by the Bioethics and Animal Well-being Committee of Instituto de Salud Carlos III, Majadahonda, Madrid, Spain (Report # CEI PI 04_2010).


Whole blood (20–50 ml) was collected from 22 HIV-1-infected antiretroviral drug-naïve individuals at diverse infection stages.

CD4+CD25+ lymphocyte isolation

PBMCs were separated by density gradient centrifugation on Ficoll. CD4+CD25+ lymphocytes were obtained through immunomagnetic separation using, sequentially, CD4+ T Cell isolation Kit II, human, and CD25 MicroBeads II, human (Miltenyi Biotec, Bergisch Gladbach, Germany), following manufacturer’s instructions.

RNA extraction and RT-PCR amplification of DS and SS HIV-1 RNAs

Total RNA was extracted using RNAeasy kit (Qiagen, Venlo, Netherlands) following manufacturer’s instructions. HIV-1 doubly and singly spliced RNAs were amplified in separate reactions by RT-PCR, followed by nested PCR, as previously described [12], with these modifications: (1) the antisense primer used for nested PCR of SS RNAs was SSD1 (CTCTCATTGCCACTGTCTTCTGCTC, HXB2 positions 6207–6231); (2) a different multiplex identifier (MID) sequence was appended to the 5’ of nested PCR primers used for each reaction, allowing for multiplexed analysis; and (3) 35 cycles were used for the nested PCR. RT-PCRs (35 cycles) were done with a mixture of SuperScript III Reverse Transcriptase (Life Technologies, Carlsbad, CA, USA), Biotaq DNA Polymerase (Bioline, London, UK), and Pfu DNA Polymerase (Stratagene, Cedar Crek, TX, USA), and nested PCRs with a mixture of Biotaq DNA Polymerase and Pfu DNA Polymerase. Locations in the HIV-1 genome of sequences recognized by primers are shown in Fig 1. PCR products were visualized by electrophoresis in 1% agarose gels and staining with SYBR Safe DNA Gel Stain (Life Technologies, Carlsbad, CA, USA). Due to budget limitations, only 12 samples were randomly selected for amplification and sequence analysis of SS RNAs among those with positive amplification for DS RNAs.


Amplified cDNA products from different samples were quantified using Quant-iT PicoGreen dsDNA Assay Kit (Life Technologies, Carlsbad, CA, USA) and Agilent 2100 Bioanalyzer High Sensitivity DNA chips (Agilent Technologies, Santa Clara, CA, USA) and equimolarly pooled at concentration of 109 molecules/μl prior to emulsion PCR. Enriched DNA beads were subjected to 400 cycles of pyrosequencing in GS Junior plus System (454 Life Sciences, Branford, CT, USA) using amplification mixes and PCR conditions recommended by the manufacturer for long amplicons. In the processing of raw reads, the most stringent analysis pipeline for long amplicons (Long Amplicons #1 pipeline, 454 Sequencing System Software Manual, v2.9, Part B, p. 27) was applied. Reads were deposited in the European Nucleotide Archive, with accession number PRJEB13105. Data associated with the submitted sequences are shown in supplementary S1 Table.

Subtype assignation

HIV-1 subtype assignation was performed using the online program COMET (COntext-based Modeling for Expeditious Typing) [59] and with phylogenetic analyses with FastTree2 [60], applying the GTR+CAT evolutionary model. Phylogenetic analyses were done using the exon 5/exon 7 fragment, common to all DS RNAs, from 20 randomly chosen DS sequences from each sample, aligned with MAFFT (Multiple Alignment using Fast Fourier Transform) v.7.215 [61]. Trees were viewed with MEGA v.5.2 [62].

Assignation of sequences to HIV-1 spliced transcripts

Sequences were assigned to known HIV-1 transcripts by mapping reads to reference sequences of HIV-1 transcripts using Burrows-Wheeler Aligner’s Smith-Waterman alignment (BWA-SW) [63]. HIV-1 reference sequences were generated by all possible combinations of mutually compatible exons of all reported HIV-1 exons of the identified subtypes, joined consecutively in the 5’-3’ order of their locations in the HIV-1 genome. The isolates used to generate reference sequences were HXB2 (subtype B), Q23_17 (subtype A), 96BW0502 (subtype C), 93BR020_1 (subtype F), and X558 (subtype G). BWA-SW parameters were adjusted empirically by comparing results to a set of manually aligned reads. Specifically, BWA-SW parameters were set to: mark multi-part alignments as secondary (-M); gap extension penalty set to 10 (-r10); maximum seeding interval set to 75 (-s 75); and Z-best set to 5 (-z 5). Sequences with ambiguous assignations with BWA-SW (i.e., those which were assigned to more than one transcript) were assigned to individual HIV-1 transcripts by alignment with reference sequences of HIV-1 spliced transcripts using MAFFT v.7.215 [61], parameterized to automatically select the appropriate strategy (—auto), with manual curation of alignments. Sequences that could not be assigned to reference transcript sequences by alignment with BWA-SW or MAFFT were mapped to the HIV-1 HXB2 reference genome using the online Sequence Locator program [64] to repeatedly align reads to the HXB2 genome, identify single exons, remove the identified exon sequence and realign the trimmed read to HXB2 until all identifiable exons were found. In all cases, identification of a new 3’ss required that the usual sequence elements of metazoan 3’ss (an adjacent AG dinucleotide and a nearby pyrimidine-rich tract) were present upstream of the putative 3’ss. Similarly, identification of a new 5’ splice site required that the highly conserved GT dinucleotide be present immediately downstream of the putative splice site. Sequences that aligned in the MAFFT analysis with the newly identified transcripts, showing coincident exon junctions, were assumed to have the same exon composition.

RT-PCR amplification and sequencing of vif transcripts

Since no vif RNAs were detected in any sample by using primers recognizing sequences common to all HIV-1 DS RNAs, they were amplified with nested PCR, following RT-PCR for SS RNAs, using a vif-specific antisense primer (CCCTAGTGGGATGTGTACTTCTGAACTTA, HXB2 positions 5192–5220) recognizing a segment between exons 2 and 3 which, among HIV-1 spliced transcripts, is present only in vif RNAs. The amplified product was subjected to bulk sequencing using ABI 3730 XL automated sequencer (Thermo Fisher Scientific, Waltham, MA USA).

PCR amplification and sequencing of proviral genome fragments

In two samples, sequences around splice site positions in the HIV-1 mid-genome portion (A1 through A5a) (which were absent in the sequenced RNAs) were obtained from proviral DNA. This was extracted from CD4+CD25+ lymphocytes using QIAamp DNA Mini Kit (Qiagen, Venlo, Netherlands) and amplified by nested PCR. Sequences and HXB2 positions of PCR primers were GGCATTCCCTACAATCCCCAAAGTC (4647–4671) and ATATGCTTTAGCATCWGATGCACA (6384–6407) in first round PCR, and AGGGGAAAGAATAATAGACATAATAGCAWCAG (4817–4848) and TCTYTCCACACAGGTACCCCATA (6342–6364) in nested PCR. PCR products were directly sequenced with ABI 3730 XL sequencer.

vif RNA and proviral DNA sequences were deposited in GenBank, under accessions KU901577- KU901587.

ResultsPCR-positive samples and clinical data

In 19 of 22 samples in which HIV-1 DS RNA amplification was attempted, PCR products of expected sizes (0.2–0.9 kb) were detected through agarose gel electrophoresis (data not shown). Of the three samples with undetectable PCR products, plasma viral loads were below the level of detection (50 copies/ml) in two and it was 106 copies/ml in one. HIV-1 SS RNA amplification was attempted in 12 of the 19 samples that had yielded positive DS RNA amplification, yielding PCR products of expected sizes (0.3–1.0 kb–no product of the size expected for vif RNA, 1.2 kb, was observed) (data not shown). Clinical data of the 19 samples with positive RT-PCR amplification of HIV-1 spliced RNAs are shown in Table 1.

Table 1
Clinical data and subtypes of samples used in this study.

Subtype determination

A total of 13,715 reads were obtained for all samples, of which 10,199 were from the DS RNA and 3,516 from the SS RNA RT-PCR amplifications. HIV-1 subtype determination with COMET assigned 15 samples to subtype B, one (SPX10) to subtype C, one (SPX19) to subtype G, one (SPX21) to subtype A (subsubtype A1), and two (SPX25 and SPX35) to subtype F (subsubtype F1). Phylogenetic analyses of the exon 5/exon 7 fragment from 20 randomly chosen DS sequences from each sample confirmed the subtype assignation of the COMET analysis (Fig 2, Table 1).

Fig 2
Phylogenetic tree of DS HIV-1 RNA sequences.

Number of sequences derived from HIV-1 transcripts

Using BWA-SW, 11,496 (83.8%) sequences were assigned to a single of the HIV-1 spliced transcripts used as references, while 2,029 (14.8%) sequences had ambiguous assignations (BWA-SW assigned them to more than one of the references), and 190 (1.4%) were unmappable to any of the reference transcripts. Of these, 68 corresponded to short reads 44–67 nucleotides (nt) long. Among the ambiguously assigned sequences, there were 110 in the DS RNA category assigned to both tat and vpr RNAs and 139 in the SS category assigned to tat, vpr, and vif RNAs. Their ambiguous assignations derived from the fact that their sequences were common to all of the assigned RNA classes, as they lacked discriminative fragments at the 5’ end which would allow assignation to a specific class. These sequences were excluded from further analyses. Another 366 sequences within the SS RNA category were ambiguously assigned to both vpr and vif RNAs, as they had sequences common to both transcripts and lacked sequences at the 5’ segment which would allow distinguishing between them. Since not a single sequence unambiguously assigned to the vif RNA transcript was detected in any sample, and unambiguous vpr RNA sequences were detected in most samples, ambiguous vpr/vif sequences were assigned to vpr RNAs. Among the ambiguously assigned sequences, there were 76 from six samples that were probable PCR-mediated artifacts. This was suspected because they lacked the usual features expected for RNA splice junctions: no known splice site was involved in the junction of discontinuous segments of the HIV-1 genome, and no GT nor AG dinucleotides were present immediately downstream of the 5’ segment and upstream of the 3’ segment, respectively, at both sides of the junction (as determined in other sequences of the corresponding sample). By alignment with reference transcripts using MAFFT and mapping sequence segments to the HXB2 genome using Sequence Locator, 2,004 ambiguous sequences could be assigned to individual HIV-1 spliced transcripts. These analyses also allowed to reassign 416 (3.6%) sequences that were incorrectly assigned by BWA-SW. There were 92 additional sequences, 7 in the assigned and 85 in the ambiguous categories, as classified by BWA-SW, that by subsequent analyses could not be unambiguously assigned to a specific HIV-1 transcript.

In total, there were 13,108 sequences which could be assigned to individual HIV-1 transcripts, of which 9,807 derived from DS RNAs and 3,301 from SS RNAs, with mean numbers per sample of 516 and 275, respectively (ranges, 203–1036 and 107–606, respectively).

Identification of new HIV-1 splice sites

In four samples, SPX10 (subtype C), SPX12 (subtype B), SPX19 (subtype G), and SPX 21 (subtype A), five 3’ss used by nef or rev RNAs mapping to unreported positions in the HIV-1 genome were identified (Fig 3).

Fig 3
Novel splice junctions identified in this study.

In SPX10 (subtype C) some nef RNAs used as 3’ss for splicing at the 3’-terminal exon two 3’ss located 20 and 32 nt downstream of the usual A7 site (at HXB2 positions 8399 and 8411, respectively). These splice sites were designated A7g and A7h, respectively, and RNAs using them had exon compositions 1.5.7g,,, 1.5.7h, and In SPX19 (subtype G), some nef RNAs and a single rev RNA-derived sequence used for splicing at the 3’-terminal exon a 3’ss located 18 nt downstream of A7 (at HXB2 position 8397) which was designated A7i. RNAs using A7i had exon compositions and 1.4a.7i. In SPX12 (subtype B), some rev RNAs used for splicing at the first coding exon a 3’ss located 16 nt upstream of A4a (at HXB2 position 5939) which was designated A4i. All RNAs using A4i had exon composition 1.3.4i.7. In SPX21 (subtype A), some rev RNAs used for splicing at the first coding exon a 3’ss located 4 nt upstream of A4a (at HXB2 position 5951), which was designated A4j. All transcripts using A4j had exon composition 1.4j.7. That the newly identified junctions represent real HIV-1 RNA splice junctions and are not PCR-mediated artifacts was inferred from the facts that in all of them a known HIV-1 5’ splice site (5’ss) was involved (Fig 3) and that the usual features of the metazoan 3’ss, i.e. an AG immediately upstream of the 3’ss and a pyrimidine-rich tract located further upstream, were present in the sequences of the corresponding viruses (Fig 4, Fig 5).

Fig 4
Sequences surrounding 3’ss used by rev, nef and env-vpu RNAs in the analyzed samples.
Fig 5
Sequences surrounding newly identified 3’ss used for splicing at the 3’-terminal exon of DS RNAs.

It should be noted that A4j is located only one nt downstream of the previously identified A4d site [11,13], and, therefore, both splice sites are mutually incompatible and could be viewed as variants of the same splice site. This incompatibility is similar to that existing between A4e and A4a, the first located only one nt upstream of the second [11]. Similarly, A4i could be viewed as a variant of A4c, located two nt upstream, since, in the hypothetical case that both sites would be present in a virus, A4i would necessarily be preceded by GAG, which is associated with inefficient cleavage [65] resulting in a most likely nonfunctional site, and, consequently, to mutual incompatibility of A4c and A4i. A similar consideration could be made regarding A7g and A7i, separated by two nt.

Of the newly identified 3’ss or variants of 3’ss, A7g, A7h, and A7i were used by small minorities of nef transcripts (S2 Table), but A4i and A4j were used by substantial proportions of rev RNAs in SPX12 and SPX21 viruses, respectively (see below).

A4i and A4j are located upstream of the coding sequence for Rev and their usage does not result in the modification or the creation of any open reading frame (Fig 4). A7i, A7g and A7h are located upstream of the Nef coding sequence and their usage would not affect the coding potential of Nef RNAs. However, in RNAs using 3’ss of the first coding exons of tat and rev RNAs, usage of A7g and A7h would result in a frameshift and usage of A7i would result in six amino acid deletions in the second coding exons of Rev and Tat proteins. It must be noted, however, that all but one sequences using A7g, A7h and A7i correspond to nef RNAs, the only exception being a rev RNA using A7i (S2 Table).

No usage of novel 5’ splice sites was detected in any of the transcripts.

Relative abundance of sequences derived from HIV-1 DS and SS RNAs according to encoded proteins


DS transcripts potentially coding for Nef, Rev, Tat, and Vpr proteins, according to the splice sites used, were detected in 19, 14, 13, and 13 samples, respectively (Fig 6A, S2 Table). In 17 samples, nef RNAs were the most abundant, in agreement with previous in vitro studies [1,2,6,9]. However, in two samples (SPX21, of A subtype, and SPX35, of F subtype) rev and tat RNAs, respectively, were more abundant than nef RNAs (Fig 6A). On average, nef RNAs represented around 70% DS RNAs, followed, in order of abundance, by rev, tat and vpr RNAs.

Fig 6
Relative abundance of RNAs coding for different proteins among (a) DS and (b) SS HIV-1 RNAs. The vertical axis represents proportions relative to all transcripts of each category. Mean proportions of all samples are shown on the right of the columns for ...


With the exclusion of ambiguous tat/vpr/vif sequences and the assumed vpr assignation of ambiguous vif/vpr sequences, as discussed above, env-vpu, tat, and vpr RNAs were detected in 12, 8, and 10 samples, respectively. No unambiguous vif RNAs were detected in any sample by using primers recognizing sequences common to all SS RNAs and pyrosequencing. However, by using a vif RNA-specific primer in the nested PCR and Sanger sequencing, vif RNAs were detected in nine samples: SPX6, SPX10, SPX12, SPX13, SPX15, SPX20, SPX23, SPX24, and SPX35 (data not shown). On average, env-vpu RNAs were the most abundant, representing around 77% SS RNAs, followed, in order of abundance, by vpr and tat RNAs (Fig 6B, S3 Table).

Incorporation of extra small noncoding exons

Incorporation of exons 2 or 3

The frequencies of incorporation of exons 2 or 3 or both into nef, rev, and DS tat RNAs are shown in Fig 7, and those corresponding to env-vpu and SS tat RNAs are shown in Fig 8.

Fig 7
Frequency of incorporation of noncoding exons in DS RNAs among (a) nef, (b) rev, and (c) tat RNAs. The vertical axis represents proportions relative to all transcripts of each class. Mean proportions of all samples are shown on the right of the columns ...
Fig 8
Frequency of incorporation of noncoding exons in SS RNAs among (a) env-vpu and (b) tat RNAs. The vertical axis represents proportions relative to all transcripts of each class. Mean proportions of all samples are shown on the right of the columns for ...

nef RNAs incorporating exons 2 or 3 were detected in 18 samples, and in 10 samples, nef transcripts incorporating one or both of these exons were the most abundant. Among samples expressing nef RNAs incorporating exons 2 or 3, inclusion of exon 3 was more frequent in 13 and that of exon 2 in 4.

Among rev RNAs, in 11 of 14 samples in which they were expressed, transcripts incorporating exons 2 or 3 were identified, and in 5 they were more abundant than transcripts lacking them. Similarly to nef RNAs, there was a preference for inclusion of exon 3, with 8 of 11 samples in which extra noncoding exons were detected expressing more abundantly transcripts incorporating exon 3.

With regard to DS tat RNAs, they incorporated exons 2 or 3 in 9 of 13 samples in which these RNAs was expressed. In contrast to nef and rev RNAs, there was an overall preference for inclusion of exon 2 over exon 3, with 6 of 9 samples showing higher abundance of RNAs including exon 2. Preference for inclusion of exon 2 was also observed among SS tat RNAs, which was seen in both samples in which extra noncoding exons were incorporated into these RNAs.

Among env-vpu RNAs, extra noncoding exons were incorporated in 7 of 12 samples, with a preference for inclusion of exon 3 (7 samples) over exon 2 (2 samples).

With regard to vpr RNAs, incorporation of exon 2 was seen in a single DS sequence of one sample.

Nef transcripts lacking noncoding exon 5

Most nef RNAs incorporate noncoding exon 5 [1,2,6], but it has been reported that a minority of nef RNAs can be generated through direct splicing from 5’ss D1 to 3’ss A7 (nef 1.7 RNAs), thus excluding exon 5 [2,6,9,35]. We found nef 1.7 RNAs in 6 samples, in which they represented a minority of nef RNAs, although in SPX23 they represented 40% nef transcripts. In one sample (SPX19, subtype G), two other nef RNA species lacking exon 5, with exon compositions 1.3.7 and, were detected at very low proportions.

Alternative 3’ss usage

Alternative 3’ss usage by rev RNAs (Fig 9A, S2 Table

Fig 9
Alternative 3’ss usage by (a) rev and (b) env-vpu RNAs. 3’ss separated by one or two nt (A4a/A4e, A4c/A4i, A4d/A4f/A4j) were grouped together. A4e is used by SPX24 and SPX35, A4d by SPX26, A4f by SPX10, A4j by SPX21, and A4i by SPX12. ...

Eight different 3’ss were used for splicing at the first coding exon of rev RNAs, A4a, A4b, A4c, A4d, A4e, A4f, A4i, and 4j (the number would be four if sites separated by one or two nt, A4a/A4e, A4c/4i, and A4d/A4f/A4j, would be grouped as variants of the same 3’ss). The proportions of rev RNAs in which usage of these 3’ss were detected are shown in Fig 9A, in which splice sites separated by one or two nt are grouped together, for the reasons explained above. A4a/A4e was preferred in 4 samples; A4b in 7; A4cand A4f each in one sample; and almost equal proportions of A4a- and A4b-using RNAs were found in one sample. With regard to rev RNAs using unusual or novel 3’ss or variants of 3’ss (A4d, A4e, A4f, A4i and A4j) their abundance was in all cases greater than 20% of total rev transcripts in the samples in which they were detected. In two samples, of subtypes B and C, A4e and A4f, were, respectively, the most commonly used 3’ss for rev RNA generation.

Usage of 3’ss A5a by nef and env-vpu RNAs (Fig 9B, S2 and S3 Tables)

3’ss A5 is used for generation of most nef and env-vpu RNAs [13,5,6]. However, an alternative 3’ss, A5a, located 4 nt downstream of A5 (at HXB2 position 5981) has been reported to be used by some nef [8,9] and env-vpu [8,9,16] RNAs. Among the analyzed samples, A5a was used by nef RNAs in 7 samples and by env-vpu RNAs in 3 samples. Surprisingly, there was no coincidence in A5a usage between env-vpu and nef RNAs, so that, in total, A5a was used by nef or env-vpu RNAs in 10 samples. The proportion of nef RNAs using A5a was less than 10% in all cases. Notably, transcripts using A5a represented 43% of env-vpu RNAs in one sample (SPX15).

Alternative 3’ss usage in the 3’-terminal exon of DS RNAs (S2 Table)

In most HIV-1 DS RNAs, 3’ss A7 is used for splicing at the 3’-terminal exon [1,2,6]. However, occasional usage of 3’ss A7a and A7b, located 24 and 28 nt, respectively, upstream of A7 (at HXB2 positions 8355 and 8351, respectively), has been reported in HXB2 [1] and p89.6 [9] isolates. We detected usage of A7b or both A7a and A7b in 4 samples. Additionally, in two samples, we detected usage of three unreported 3’ss for splicing at the 3’-terminal exon, which were designated A7g, A7h, and A7i. The number of samples in which the alternative 3’ss were used was five: A7a and A7b in SPX2 and SPX24 (subtype B), A7b in SPX8 (subtype B), A7g and A7h in SPX10 (subtype C), and A7b and A7i in SPX19 (subtype G). The alternative sites were used by nef RNAs in all five samples, by rev RNAs in two, and by tat RNAs in two. The proportions of RNAs using these sites were in each case less than 5% of nef, rev, and tat RNAs. Regarding A7g, A7h, and A7i, each was used in around 2% of nef RNAs in samples in which they were detected. In addition, usage of A7i was detected in 1 of 88 rev RNAs in SPX19.

Alternative 3’ss usage by env-vpu RNAs (Fig 9B, S3 Table)

Six different 3’ss were used for splicing at the env-vpu coding exon: A5, A5a, A4a, A4b, A4c, and A4e (the number would be five if A4e would be considered a variant of adjacent A4a). The proportions of env-vpu RNAs in which usage of these 3’ss were detected are shown in Fig 9B. A5 was preferred in all env-vpu RNAs, with exclusive A5 usage in five, although, as stated above, in SPX15 almost half env-vpu RNAs used A5a. Surprisingly, in the subtype C sample SPX10, no env-vpu RNAs splicing at A4f (the 3’ss preferentially used by rev RNAs in this sample) were detected, with A4c being the second 3’ss used by env-vpu RNAs after A5.


This study provides new data on in vivo HIV-1 RNA splice site usage in viruses of different subtypes (A, B, C, F, and G), for which previously available data were scarce. A high diversity of spliced transcripts were identified through pyrosequencing, several of which involve usage of five previously unreported splice sites (Fig 3, Fig 4, Fig 5), four of them identified in non-B subtypes. The new splice sites correspond to 3’ss used by nef or rev RNAs. Although the usage of the three new sites at the 3’-terminal exon of DS RNAs (designated A7g, A7h, and A7i) was uncommon, usage of both newly identified 3’ss for splicing at the first rev coding exon, named A4i and A4j, was relatively frequent (Fig 9A). Usage of the new 3’ss was associated with the presence of AG dinucleotides immediately upstream of the splice sites and a pyrimidine-rich tract further upstream (Fig 4, Fig 5). As explained above, A4i and A4j map to positions in the HIV-1 genome located just one or two nt from previously reported A4c and A4d sites, respectively, and, therefore, they could be viewed as variants of these sites rather than new splice sites. Similarly, A7g and A7i, separated by two nt, could be viewed as variants of the same splice site. It should be pointed out, however, that reported HIV-1 splice sites separated by one or two nt, such as A4a and A4e, or A4d and A4f, have been considered and named as distinct splice sites [11,12]. In accordance with the scanning model of 3’ss recognition by the splicing machinery [65,66], the nucleotide after the first AG encountered downstream of the branch point is used as 3’ss, unless another downstream AG is located in close proximity, which can compete for 3’ss recognition. The competitiveness of the AG varies according to the nucleotide preceding it, following this order: CAG ≈ UAG > AAG > GAG [66]. This model is consistent with the usage of novel and unusual 3’ss by rev RNAs observed in our study (Fig 4). Thus, we see that in SPX10, the A4b site, preceded by UAG, is used in 17.7% of rev RNAs, even though upstream of it there is the A4f site, preceded by CAG; and that A4b, with preceding UAG, is used preferentially to the upstream 3’ splice sites A4j in SPX21 and A4e in SPX35, respectively, which are preceded by AAG. However, the proposed hierarchy of 3’ss usage is not followed in SPX24. In this virus, the upstream site, A4e, with preceding AAG, is preferentially used over A4b, with preceding UAG, a preference also observed in env-vpu RNAs. Among the unusual 3’ss, we observed the preferential usage of A4f by rev RNAs of a subtype C virus (SPX10), confirming a previous observation in subtype C viruses in an in vitro infection assay [12]. However, in contrast to the previous study, A4b was used by a substantial proportion of rev transcripts of SPX10. With A4i and A4j sites, the number of 3’ss mapping to different positions in the HIV-1 genome reported to be used by rev RNAs is ten. The great multiplicity of splice sites used by rev transcripts may derive from the great variability of the Tat coding sequence [67], where rev 3’ss are located. Mutations in this region may give rise to new AG dinucleotides, generating new 3’ss recognized by the splicing machinery scanning downstream of a branch point.

With regard to the newly identified 3’ss used for splicing at the 3’-terminal exon of DS transcripts (A7g, A7h, A7i), the presence of the upstream AG and a pyrimidine-rich tract may not explain by themselves their usage in SPX10 and SPX19, since other viruses here analyzed have these sequence features in the same genome region (Fig 5). The difference in splice site usage may be explained by the fact that SPX10 and SPX19 have the human consensus branch point sequence yUnAy [68] (with the lower case denoting less conserved nucleotides) upstream of the A7g/A7h/A7i sites, which is absent from the other viruses, except the subtype A virus SPX21 (Fig 5). In this virus, sequence features (yUnAy motif, pyrimidine-rich tract, AG dinucleotide) could also predict usage of a 3’ss at the nt position between A7g and A7h; failure to detect it could be explained by the relatively low number of nef RNA sequences, among which usage of all but one of the new sites close to A7 was detected, obtained for SPX21, compared to SPX10 or SPX19, and by the low frequency of usage of these sites. Although the pyrimidine-rich tracts located between the proposed branch points and the 3’ss in SPX10 and SPX19 have only seven pyrimidines interspersed with purines, there are reported 3’ss for which the pyrimidine contents of the upstream sequences were much lower than those seen for A7g, A7h, and A7i [69,70]. Failure to detect usage of A7h in SPX19, in spite of having the same yUnAy and adjacent AG motifs as SPX10 (Fig 5), may derive from the fact that the CAG sequence upstream of A7i in SPX19 could make it a stronger 3’ss, compared to A7g in SPX10, which is preceded by AAG, thus preventing usage of the potential 3’ss located 14 nt downstream [66].

Other unusual splice sites detected in this study were A5a, A7a, and A7b. A5a, located 4 nt downstream of A5, was previously identified in a small minority of env transcripts in two isolates [9,18], and in vivo in one of five viruses [8]. In the present study, usage of A5a was detected in 10 (53%) samples. nef or env-vpu RNAs using A5a were a small minority relative to those using A5, except in one sample in which 43% of env-vpu transcripts used A5a (Fig 9B). No unusual sequence feature was found that would explain the high frequency of A5a usage by env-vpu RNAs in this sample, as the sequence surrounding A5 and A5a was CAGGAAGA (with the underline denoting the splice sites), which is highly conserved in group M viruses. Usage of A7a or A7b, previously reported only in the HXB2 [1] and p89.6 [9] isolates, was detected in three samples, mostly in nef, but also in tat and rev RNAs, representing a small minority within each RNA class.

In addition to the new and unusual HIV-1 transcripts identified in this study, a mention should also be made to previously reported unusual HIV-1 transcripts that were not detected. These include RNAs containing exon 6D, delimited by 3’ss A6 and 5’ss D5, coding for the chimeric protein Tev/Tnv [1,14,15], or using splice sites D2a [12], A4g [12], A4h [13], A7c [17], A1A [18], D1A [18], or cryptic splice sites whose usage was detected through deep sequencing in a very small minority of transcripts in the p89.6 isolate [9]. Other 3’ss used by short RNAs splicing near the HIV-1 genome’s 3’ end [79] were not detected in our assay because the primers were not designed for their amplification. These RNAs were not the subject of the current study, due to their reported relatively infrequent detection in vivo and their still undefined role in HIV-1 life cycle. Future studies will need to be carried out to better define their abundance, splice site usage and function.

Usage of splice sites reported to be commonly used by HIV-1 isolates failed to be detected in some samples (S2 and S3 Tables): 3’ss for rev RNA in four samples, A1 in three samples, A2 in one sample, and A3 in six samples. Sequence analysis around these 3’ss revealed the presence of the usual upstream AG dinucleotide and pyrimidine-rich tracts (Fig 4, S1 Fig). Therefore, lack of detection of RNAs using these splice sites in some samples may not be caused by mutations in their essential elements, but rather by expression levels below the level of detection of our assay.

This study was the first to analyze splicing patterns in viruses of HIV-1 subtypes A, F, and G, and in vivo splicing patterns in a subtype C virus. In these viruses, splice site usage was largely consistent with that seen in subtype B viruses, but we note that four of the five newly identified splice sites or splice site variants were found in non-subtype B viruses. One of these was A4j, used by some rev RNAs in the subtype A1 virus SPX21. However the AG dinucleotide adjacent to this site is found in none of the available subtype A1 near full-length genomes sequences [71], and, therefore, A4j usage would probably be rare in subtype A viruses. In the subtype C virus, preferential A4f usage by rev RNAs, previously reported in two of three isolates [12], was confirmed. A4f usage is predicted in most subtype C viruses, considering that the AG dinucleotide immediately upstream is present in most of them (S2 Fig). Usage of A4e (which could be viewed as a variant of A4a shifted one nt upstream) detected in the subtype F virus SPX35, is also predictable in the great majority of F1 subtype viruses, considering that the AG dinucleotide upstream of A4e is present in all available subtype F1 near full-length genome sequences (for the same reason, A4e would also be predicted to be used by most CRF02_AG viruses) (S2 Fig). With regard to the newly identified 3’ss used for splicing at the 3’-terminal exon, the yUnAy motif and downstream pyrimidine-rich and CAG sequences present in the consensus sequences of subtypes C, F1 and G and of CRF02_AG could predict usage of A7h in most viruses of subtypes C and F1, and of A7i in most viruses of subtype G and of CRF02_AG (S3 Fig).

Many of the quantitative data on relative expression of HIV-1 RNAs obtained in this study are consistent with previously published data [1,2,6,8,9]. These include (1) the greater relative abundance of nef and env-vpu RNAs among DS and SS transcripts, respectively, in most samples; (2) the order of relative abundance nef>rev>tat>vpr among DS RNAs in a majority of samples; (3) the preferential incorporation of exon 3 in nef, rev, and env-vpu RNAs, and of exon 2 in tat RNAs; (4) the relative rarity of nef 1.7 RNAs compared to nef RNAs incorporating exon 5; and (5) the infrequent use of A5a or of A7a/A7b, compared to A5 and A7, respectively. However, there are other data that differ from previous reports. One of these is the substantially greater relative abundance of vpr RNAs among SS RNAs (mean 14.7%, vs. 8.5% for SS tat RNAs), with 7 of 12 samples showing greater SS vpr RNA-derived than SS tat RNA-derived PCR products. Greater SS vpr than SS tat RNA expression has also been observed by us in an in vitro acute infection assay of PBMCs by HIV-1 primary isolates (unpublished data). The much lower relative abundance of DS vpr detected by us (mean 2.3% of DS RNAs) could be explained by nonsense-mediated RNA decay of DS vpr transcripts, which contain a stop codon more than 50–55 nt upstream of an exon-exon junction [72], and by the fact that DS vpr RNAs frequently undergo rapid splicing to nef, rev and tat RNAs [4]. For the interpretation of the quantitative data, it may be important to take into consideration the possible existence of biases derived from (1) unequal amplification efficiencies of templates of different lengths coamplified in the same reaction; and (2) the relatively low abundance of HIV-1 spliced transcripts in lymphocytes from HIV-1-infected individuals compared with in vitro-cultured cells. With regard to the length-dependent bias, it is shared with other PCR-based assays employed in previous studies in which relative quantifications of spliced RNAs were reported [2,6,9]. The relatively low abundance of HIV-1 spliced transcripts in lymphocytes from HIV-1-infected individuals could explain the failure to detect in some samples less abundant transcripts (i.e., those different from nef or env-vpu RNAs among DS and SS RNAs, respectively), which might be below the detection threshold in our assay. Even with these methodological caveats in mind, considering the agreement of many of our quantitative data with previously published data, those differing from them, particularly those observed in a majority of samples, should not be dismissed, pending confirmation by other authors and with different assays.

Since in this study in vivo expression of HIV-1 spliced RNAs was examined, it should be considered that in this setting there are nonviral factors that could influence HIV-1 splice site usage, including host genetic factors and disease stage. These are out of the intended scope of the present study and were not analyzed.

In conclusion, in this study, in which we examine in vivo expression of individual HIV-1 spliced transcripts through pyrosequencing, using samples corresponding to viruses of five different subtypes, we identified five new splice sites or splice site variants used by HIV-1 nef and rev RNAs. Four of these were detected in viruses of non-B subtypes, which anticipates finding greater variability in HIV-1 RNA splice site usage by analyzing larger number of viruses of different genetic forms. Further work will be required to obtain mechanistic insights into the regulation of the usage of the newly identified splice sites through the action of nearby enhancer or silencer motifs or through RNA secondary structures [31,32,73]. Many data on relative expression among the HIV-1 spliced RNA categories were consistent with previous reports based on in vitro assays, but some were different, which may need to be confirmed in future studies. Since RNA splicing is an essential step in the HIV-1 life cycle, the results here reported may be of relevance for the development of therapeutic agents aimed at interfering with HIV-1 splicing mechanisms, some of which have shown promising results in in vitro assays [7477].

Supporting Information

S1 Fig

Sequences surrounding A1, A2, and A3 3’ss in samples in which their usage was not detected.

AG dinucleotides immediately upstream of these sites are in red and pyrimidine-rich tracts upstream of these AGs are underlined.


S2 Fig

Consensus sequences of most globally prevalent HIV-1 clades around 3’ss of rev and nef RNAs.

Names and HXB2 positions of 3’ss used by rev and nef RNAs in this study are indicated above the alignment. AG dinucleotides potentially used as 3’ss are in red and pyrimidine-rich tracts upstream of these AGs are underlined, The Rev start codon is boxed across all sequences.


S3 Fig

Consensus sequences of most globally prevalent HIV-1 clades at the 5’ segment of exon 7.

Names and HXB2 positions of 3’ss newly identified this study (A7g, A7h, A7i) are indicated above the alignment. AG dinucleotides adjacent to potentially used A7h and A7i sites, according to the presence of and adjacent upstream A, C or T, and further upstream pyrimidine-rich tract (underlined) and yUnAy motif (in blue), are in red.


S1 Table

Data associated with sequence files submitted to the European Nucleotide Archive.


S2 Table

Distribution of HIV-1 doubly spliced RNAs identified in each sample.


S3 Table

Distribution of HIV-1 singly spliced RNAs identified in each sample.



We thank Pilar Jiménez, from Genomics Unit, Centro Nacional de Microbiología, for help in 454 sequencing.

Funding Statement

This work was supported by the Francisco Díez-Fuertes is supported by the Sara Borrell postdoctoral Program of the Spanish Government 2012 CD12/00515. This work was also supported by Ministerio de Economía y Competitividad, Spain (URL: Grant # SAF2010-20961, Grant # SAF2013-48488-P to MMT and Instituto de Salud Carlos III (URL: Grant # MPY 1194/12 to MMT. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Data Availability

Data Availability

All relevant data are within the paper and its Supporting Information files.


1. Schwartz S, Felber BK, Benko DM, Fenyo EM, Pavlakis GN. Cloning and functional analysis of multiply spliced mRNA species of human immunodeficiency virus type 1. J Virol. 1990;64:2519–2529. [PMC free article] [PubMed]
2. Robert-Guroff M, Popovic M, Gartner S, Markham P, Gallo RC, Reitz MS. Structure and expression of tat-, rev-, and nef-specific transcripts of human immunodeficiency virus type 1 in infected lymphocytes and macrophages. J Virol. 1990;64:3391–3398. [PMC free article] [PubMed]
3. Schwartz S, Felber BK, Fenyo EM, Pavlakis GN. Env and Vpu proteins of human immunodeficiency virus type 1 are produced from multiple bicistronic mRNAs. J Virol. 1990;64:5448–5456. [PMC free article] [PubMed]
4. Schwartz S, Felber BK, Pavlakis GN. Expression of human immunodeficiency virus type 1 vif and vpr mRNAs is Rev-dependent and regulated by splicing. Virology. 1991;183:677–686. [PubMed]
5. Arrigo SJ, Weitsman S, Zack JA, Chen IS. Characterization and expression of novel singly spliced RNA species of human immunodeficiency virus type 1. J Virol. 1990;64:4585–4588. [PMC free article] [PubMed]
6. Purcell DF, Martin MA. Alternative splicing of human immunodeficiency virus type 1 mRNA modulates viral protein expression, replication, and infectivity. J Virol. 1993;67:6365–6378. [PMC free article] [PubMed]
7. Smith J, Azad A, Deacon N. Identification of two novel human immunodeficiency virus type 1 splice acceptor sites in infected T cell lines. J Gen Virol. 1992;73(Pt 7):1825–1828. [PubMed]
8. Carrera C, Pinilla M, Pérez-Álvarez L, Thomson MM. Identification of unusual and novel HIV type 1 spliced transcripts generated in vivo. AIDS Res Hum Retroviruses 2010;26:815–820. doi: 10.1089/aid.2010.0011 [PubMed]
9. Ocwieja KE, Sherrill-Mix S, Mukherjee R, Custers-Allen R, David P, Brown M, et al. Dynamic regulation of HIV-1 mRNA populations analyzed by single-molecule enrichment and long-read sequencing. Nucleic Acids Res. 2012;40:10345–10355. doi: 10.1093/nar/gks753 [PMC free article] [PubMed]
10. Neumann M, Harrison J, Saltarelli M, Hadziyannis E, Erfle V, Felber BK, et al. Splicing variability in HIV type 1 revealed by quantitative RNA polymerase chain reaction. AIDS Res Hum Retroviruses. 1994;10:1531–1542. [PubMed]
11. Bilodeau PS, Domsic JK, Stoltzfus CM. Splicing regulatory elements within tat exon 2 of human immunodeficiency virus type 1 (HIV-1) are characteristic of group M but not group O HIV-1 strains. J Virol. 1999;73:9764–9772. [PMC free article] [PubMed]
12. Delgado E, Carrera C, Nebreda P, Fernández-García A, Pinilla M, García V, et al. Identification of new splice sites used for generation of rev transcripts in human immunodeficiency virus type 1 subtype C primary isolates. PLoS One. 2012;7:e30574 doi: 10.1371/journal.pone.0030574 [PMC free article] [PubMed]
13. Vega Y, Delgado E, Carrera C, Nebreda P, Fernández-García A, Cuevas MT, et al. Identification of new and unusual rev and nef transcripts expressed by an HIV type 1 primary isolate. AIDS Res Hum Retroviruses. 2013;29:1075–1078. doi: 10.1089/AID.2013.0053 [PMC free article] [PubMed]
14. Benko DM, Schwartz S, Pavlakis GN, Felber BK. A novel human immunodeficiency virus type 1 protein, tev, shares sequences with tat, env, and rev proteins. J Virol. 1990;64:2505–2518. [PMC free article] [PubMed]
15. Salfeld J, Gottlinger HG, Sia RA, Park RE, Sodroski JG, Haseltine WA. A tripartite HIV-1 tat-env-rev fusion protein. EMBO J. 1990;9:965–970. [PubMed]
16. Furtado MR, Balachandran R, Gupta P, Wolinsky SM. Analysis of alternatively spliced human immunodeficiency virus type-1 mRNA species, one of which encodes a novel tat-env fusion protein. Virology. 1991;185:258–270. [PubMed]
17. Berkhout B, van Wamel JL. Identification of a novel splice acceptor in the HIV-1 genome: independent expression of the cytoplasmic tail of the envelope protein. Arch Virol. 1996;141:839–855. [PubMed]
18. Lützelberger M, Reinert LS, Das AT, Berkhout B, Kjems J. A novel splice donor site in the gag-pol gene is required for HIV-1 RNA stability. J Biol Chem. 2006;281:18644–18651. [PubMed]
19. Kim SY, Byrn R, Groopman J, Baltimore D. Temporal aspects of DNA and RNA synthesis during human immunodeficiency virus infection: evidence for differential gene expression. J Virol 1989;63:3708–3713. [PMC free article] [PubMed]
20. Klotman ME, Kim S, Buchbinder A, DeRossi A, Baltimore D, Wong-Staal F. Kinetics of expression of multiply spliced RNA in early human immunodeficiency virus type 1 infection of lymphocytes and monocytes. Proc Natl Acad Sci U S A. 1991;88:5011–5015. [PubMed]
21. Staffa A, Cochrane A. The tat/rev intron of human immunodeficiency virus type 1 is inefficiently spliced because of suboptimal signals in the 3' splice site. J Virol. 1994;68:3071–3079. [PMC free article] [PubMed]
22. O'Reilly MM, McNally MT, Beemon KL. Two strong 5' splice sites and competing, suboptimal 3' splice sites involved in alternative splicing of human immunodeficiency virus type 1 RNA. Virology. 1995;213:373–385. [PubMed]
23. Si Z, Amendt BA, Stoltzfus CM. Splicing efficiency of human immunodeficiency virus type 1 tat RNA is determined by both a suboptimal 3' splice site and a 10 nucleotide exon splicing silencer element located within tat exon 2. Nucleic Acids Res. 1997;25:861–867. [PMC free article] [PubMed]
24. Swanson AK, Stoltzfus CM. Overlapping cis sites used for splicing of HIV-1 env/nef and rev mRNAs. J Biol Chem. 1998;273:34551–34557. [PubMed]
25. Madsen JM, Stoltzfus CM. A suboptimal 5' splice site downstream of HIV-1 splice site A1 is required for unspliced viral mRNA accumulation and efficient virus replication. Retrovirology. 2006;3:10 [PMC free article] [PubMed]
26. Stoltzfus CM. Regulation of HIV-1 alternative RNA splicing and its role in virus replication. Adv Virus Res. 2009;74:1–40. doi: 10.1016/S0065-3527(09)74001-1 [PubMed]
27. Riggs NL, Little SJ, Richman DD, Guatelli JC. Biological importance and cooperativity of HIV-1 regulatory gene splice acceptors. Virology. 1994;202:264–271. [PubMed]
28. Wentz MP, Moore BE, Cloyd MW, Berget SM, Donehower LA. A naturally arising mutation of a potential silencer of exon splicing in human immunodeficiency virus type 1 induces dominant aberrant splicing and arrests virus production. J Virol. 1997;71:8542–8551. [PMC free article] [PubMed]
29. Mandal D, Feng Z, Stoltzfus CM. Gag-processing defect of human immunodeficiency virus type 1 integrase E246 and G247 mutants is caused by activation of an overlapping 5' splice site. J Virol. 2008;82:1600–1604. [PMC free article] [PubMed]
30. Erkelenz S, Hillebrand F, Widera M, Theiss S, Fayyaz A, Degrandi D, et al. Balanced splicing at the Tat-specific HIV-1 3'ss A3 is critical for HIV-1 replication. Retrovirology. 2015;12:29 doi: 10.1186/s12977-015-0154-8 [PMC free article] [PubMed]
31. Abbink TE, Berkhout B. RNA structure modulates splicing efficiency at the human immunodeficiency virus type 1 major splice donor. J Virol. 2008;82:3090–3098. [PMC free article] [PubMed]
32. Mueller N, van Bel N, Berkhout B, Das AT HIV-1 splicing at the major splice donor site is restricted by RNA structure. Virology. 3014;468–470:609–620. doi: 10.1016/j.virol.2014.09.018 [PubMed]
33. Jacquenet S, Decimo D, Muriaux D, Darlix JL: Dual effect of the SR proteins ASF/SF2, SC35 and 9G8 on HIV-1 RNA splicing and virion production. Retrovirology. 2005;2:33 [PMC free article] [PubMed]
34. Madsen JM, Stoltzfus CM. An exonic splicing silencer downstream of the 3' splice site A2 is required for efficient human immunodeficiency virus type 1 replication. J Virol. 2005;79:10478–10486. [PMC free article] [PubMed]
35. Sonza S, Mutimer HP, O'Brien K, Ellery P, Howard JL, Axelrod JH, et al. Selectively reduced tat mRNA heralds the decline in productive human immunodeficiency virus type 1 infection in monocyte-derived macrophages. J Virol. 2002;76:12611–12621. [PMC free article] [PubMed]
36. Chang ST, Sova P, Peng X, Weiss J, Law GL, Palermo RE, et al. Next-generation sequencing reveals HIV-1-mediated suppression of T cell activation and RNA processing and regulation of noncoding RNA expression in a CD4+ T cell line. MBio. 2011;4:e00549. [PMC free article] [PubMed]
37. Schnittman SM, Greenhouse JJ, Lane HC, Pierce PP, Fauci AS. Frequent detection of HIV-1-specific mRNAs in infected individuals suggests ongoing active viral expression in all stages of disease. AIDS Res Hum Retroviruses. 1991; 7:361–7. [PubMed]
38. Seshamma T, Bagasra O, Trono D, Baltimore D, Pomerantz RJ. Blocked early-stage latency in the peripheral blood cells of certain individuals infected with human immunodeficiency virus type 1. Proc Natl Acad Sci U S A. 1992;89:10663–10667. [PubMed]
39. Michael NL, Vahey M, Burke DS, Redfield RR. Viral DNA and mRNA expression correlate with the stage of human immunodeficiency virus (HIV) type 1 infection in humans: evidence for viral replication in all stages of HIV disease. J Virol. 1992;66:310–316. [PMC free article] [PubMed]
40. Michael NL, Mo T, Merzouki A, O'Shaughnessy M, Oster C, Burke DS, et al. Human immunodeficiency virus type 1 cellular RNA load and splicing patterns predict disease progression in a longitudinally studied cohort. J Virol. 1995;69:1868–1877. [PMC free article] [PubMed]
41. Arens M, Joseph T, Nag S, Miller JP, Powderly WG, Ratner L. Alterations in spliced and unspliced HIV-1-specific RNA detection in peripheral blood mononuclear cells of individuals with varying CD4-positive lymphocyte counts. AIDS Res Hum Retroviruses. 1993;9:1257–1263. [PubMed]
42. Saksela K, Stevens CE, Rubinstein P, Taylor PE, Baltimore D. HIV-1 messenger RNA in peripheral blood mononuclear cells as an early marker of risk for progression to AIDS. Ann Intern Med. 1995;123:641–648. [PubMed]
43. Bagnarelli P, Valenza A, Menzo S, Sampaolesi R, Varaldo PE, Butini L, et al. Dynamics and modulation of human immunodeficiency virus type 1 transcripts in vitro and in vivo. J Virol. 1996;70:7603–7613. [PMC free article] [PubMed]
44. Stellbrink HJ, van Lunzen J, Hufert FT, Froschle G, Wolf-Vorbeck G, Zollner B, et al. Asymptomatic HIV infection is characterized by rapid turnover of HIV RNA in plasma and lymph nodes but not of latently infected lymph-node CD4+ T cells. AIDS. 1997;11:1103–1110. [PubMed]
45. Furtado MR, Kingsley LA, Wolinsky SM. Changes in the viral mRNA expression pattern correlate with a rapid rate of CD4+ T-cell number decline in human immunodeficiency virus type 1-infected individuals. J Virol. 1995;69:2092–2100. [PMC free article] [PubMed]
46. Comar M, Simonelli C, Zanussi S, Paoli P, Vaccher E, Tirelli U, et al. Dynamics of HIV-1 mRNA expression in patients with long-term nonprogressive HIV-1 infection. J Clin Invest. 1997;100:893–903. [PMC free article] [PubMed]
47. Brachtel EF, Mascola JR, Wear DJ, Ehrenberg PK, Dayhoff DE, Sanders-Buell E, et al. Demonstration of de novo HIV type 1 production by detection of multiply spliced and unspliced HIV type 1 RNA in paraffin-embedded tonsils. AIDS Res Hum Retroviruses. 2002;18:785–90. [PubMed]
48. Pasternak AO, Jurriaans S, Bakker M, Berkhout B, Lukashov VV. Steady increase in cellular HIV-1 load during the asymptomatic phase of untreated infection despite stable plasma viremia. AIDS. 2010;1641–9. doi: 10.1097/QAD.0b013e32833b3171 [PubMed]
49. Saltarelli MJ, Hadziyannis E, Hart CE, Harrison JV, Felber BK, Spira TJ, et al. Analysis of human immunodeficiency virus type 1 mRNA splicing patterns during disease progression in peripheral blood mononuclear cells from infected individuals. AIDS Res Hum Retroviruses. 1996;12:1443–1456. [PubMed]
50. Bruggeman LA, Thomson MM, Nelson PJ, Kopp JB, Rappaport J, Klotman PE, et al. Patterns of HIV-1 mRNA expression in transgenic mice are tissue-dependent. Virology. 1994;202:940–948. [PubMed]
51. Michael NL, Morrow P, Mosca J, Vahey M, Burke DS, Redfield RR. Induction of human immunodeficiency virus type 1 expression in chronically infected cells is associated primarily with a shift in RNA splicing patterns. J Virol. 1991;65:7084. [PMC free article] [PubMed]
52. Spina CA, Guatelli JC, Richman DD. Establishment of a stable, inducible form of human immunodeficiency virus type 1 DNA in quiescent CD4 lymphocytes in vitro. J Virol. 1995;69:2977–2988. [PMC free article] [PubMed]
53. Pomerantz RJ, Trono D, Feinberg MB, Baltimore D. Cells nonproductively infected with HIV-1 exhibit an aberrant pattern of viral RNA expression: a molecular model for latency. Cell. 1990;61:1271–1276. [PubMed]
54. Butera ST, Roberts BD, Lam L, Hodge T, Folks TM. Human immunodeficiency virus type 1 RNA expression by four chronically infected cell lines indicates multiple mechanisms of latency. J Virol. 1994;68:2726–2730. [PMC free article] [PubMed]
55. Wu Y, Marsh JW. Early transcription from nonintegrated DNA in human immunodeficiency virus infection. J Virol. 2003;77:10376–10382. [PMC free article] [PubMed]
56. Borvak J, Chou CS, Bell K, Van DG, Zola H, Ramilo O, et al. Expression of CD25 defines peripheral blood mononuclear cells with productive versus latent HIV infection. J Immunol. 1995;155:3196–3204. [PubMed]
57. Biancotto A, Iglehart SJ, Vanpouille C, Condack CE, Lisco A, Ruecker E, et al. HIV-1 induced activation of CD4+ T cells creates new targets for HIV-1 infection in human lymphoid tissue ex vivo. Blood. 2008;111:699–704. [PubMed]
58. Ramilo O, Bell KD, Uhr JW, Vitetta ES. Role of CD25+ and CD25- T cells in acute HIV infection in vitro. J Immunol. 1993;150:5202–5208. [PubMed]
59. Struck D, Lawyer G, Ternes AM, Schmit JC, Bercoff DP. COMET: adaptive context-based modeling for ultrafast HIV-1 subtype identification. Nucleic Acids Res. 2014;42:e144 doi: 10.1093/nar/gku739 [PMC free article] [PubMed]
60. Price MN, Dehal PS, Arkin AP. FastTree 2—approximately maximum-likelihood trees for large alignments. PLoS One. 2010;5:e9490 doi: 10.1371/journal.pone.0009490 [PMC free article] [PubMed]
61. Katoh K, Standley DM. MAFFT multiple sequence alignment software version 7: improvements in performance and usability. Mol Biol Evol. 2013;30:772–780. doi: 10.1093/molbev/mst010 [PMC free article] [PubMed]
62. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol. 201;28:2731–2739. doi: 10.1093/molbev/msr121 [PMC free article] [PubMed]
63. Li H, Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009;25:1754–1760. doi: 10.1093/bioinformatics/btp324 [PMC free article] [PubMed]
64. HIV Sequence Database. HIV Sequence Locator. Available:
65. Smith CW, Porro EB, Patton JG, Nadal-Ginard B. Scanning from an independently specified branch point defines the 3’ splice site of mammalian introns. Nature. 342: 243–247. [PubMed]
66. Smith CW, Chu TT, Nadal-Ginard B. Scanning and competition between AGs are involved in 3' splice site selection in mammalian introns. Mol Cell Biol. 1993;13:4939–4952. [PMC free article] [PubMed]
67. Korber B, Gaschen B, Yusim K, Thakallapally R, Kesmir C, Detours V. Evolutionary and immunological implications of contemporary HIV-1 variation. Br Med Bull. 2001; 58: 19–42. [PubMed]
68. Gao K, Masuda A, Matsuura T, Ohno K. Human branch point consensus sequence is yUnAy. Nucleic Acids Res. 2008; 36: 2257–2267. doi: 10.1093/nar/gkn073 [PMC free article] [PubMed]
69. Shelley CS, Baralle BE. Deletion analysis of a unique 3’ splice site indicates that alternating guanine and thymine residues represent an efficient splicing signal. Nucleic Acids Res. 1987; 9:3787–3799. [PMC free article] [PubMed]
70. Habara Y, Doshita M, Hirozawa S, Yokono Y, Yagi M, Takeshima Y, et al. A strong exonic splicing enhancer in dystrophin exon 19 achieve proper splicing without an upstream polypyrimidine tract. J. Biochem. 2008;143:303–310. [PubMed]
71. HIV Sequence Database. Available:
72. Kervestin S, Jacobson A. NMD: a multifaceted response to premature translational termination. Nat Rev Mol Cell Biol. 2012; 13:700–712. doi: 10.1038/nrm3454 [PMC free article] [PubMed]
73. Jacquenet S, Ropers D, Bilodeau PS, Damier L, Mougin A, Stoltzfus CM, et al. Conserved stem-loop structure in the HIV-1 RNA region containing the A3 3’ splice site and its cis-regulatory element: possible involvement in RNA splicing. Nucleic Acids Res. 2001;29:464–478. [PMC free article] [PubMed]
74. Mandal D, Feng Z, Stoltzfus CM. Excessive RNA splicing and inhibition of HIV-1 replication induced by modified U1 small nuclear RNAs. J Virol. 2010;84:12790–12800. doi: 10.1128/JVI.01257-10 [PMC free article] [PubMed]
75. Asparuhova MB, Marti G, Liu S, Serhan F, Trono D, Schumperli D. Inhibition of HIV-1 multiplication by a modified U7 snRNA inducing Tat and Rev exon skipping. J Gene Med. 2007;9:323–334. [PubMed]
76. Bakkour N, Lin YL, Maire S, Ayadi L, Mahuteau-Betzer F, Nguyen CH, et al. Small-molecule inhibition of HIV pre-mRNA splicing as a novel antiretroviral therapy to overcome drug resistance. PLoS Pathog. 2007;3:1530–1539. [PMC free article] [PubMed]
77. Zhabokritsky A, Mansouri S, Hudak KA. Pokeweed antiviral protein alters splicing of HIV-1 RNAs, resulting in reduced virus production. RNA. 2014;20:1238–1247. doi: 10.1261/rna.043141.113 [PubMed]

Articles from PLoS ONE are provided here courtesy of Public Library of Science